Completed OBSERVATIONAL NCT04138589

Effect of Lumacaftor/Ivacaftor in Children With Cystic Fibrosis Homozygote for F508del on Small Airway Function (ROOTS)

Real World Data of the Effect of Lumacaftor/Ivacaftor Therapy in Children With Cystic Fibrosis Homozygote for F508del on Small Airway Function

Sponsor: Marien Hospital Wesel

Conditions Cystic Fibrosis in Children

Updated 7 times since 2019 Last updated: Nov 28, 2023 Started: Nov 1, 2017 Primary completion: Jul 19, 2022 Completion: Jul 19, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04138589, this observational or N/A phase trial focuses on Cystic Fibrosis in Children and remains completed. Sponsored by Marien Hospital Wesel, it has been updated 7 times since 2017, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Dec 2023 — Jul 2024 [monthly]

Completed

Status: Unknown Status → Completed
Dec 2022 — Dec 2023 [monthly]

Unknown Status

Status: Recruiting → Unknown Status
Jan 2021 — Dec 2022 [monthly]

Recruiting

▶ Show 2 earlier versions

Dec 2020 — Jan 2021 [monthly]

Recruiting
Nov 2019 — Dec 2020 [monthly]

Recruiting

First recorded

Nov 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Marien Hospital Wesel
University Medical Center Groningen
Vertex Pharmaceuticals Incorporated

Data source: University Medical Center Groningen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Düsseldorf, Germany
• Groningen, Netherlands